Viewing Study NCT06475820

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:19 AM
Ignite Modification Date: 2026-01-15 @ 3:51 PM
Study NCT ID: NCT06475820
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-08-23
First Post: 2024-05-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Lymphoblastic Leukemia View
None Acute Myeloid Leukemia View
None Biphenotypic Acute Leukemia View
None Malignant Lymphoma View
None Myelodysplastic Syndromes View
Keywords:

Keywords

Keyword Brief Keyword Text View
None vedolizumab View
None hematoblastosis View
None ALL View
None AML View
None children View
None young adults View
None graft versus host disease View
None Hematopoetic stem cell transplantation View
None posttransplant cyclophosphamide View